| Trial ID: | L6262 |
| Source ID: | NCT00239707
|
| Associated Drug: |
Gip
|
| Title: |
GIP: Glucose-dependent Insulinotropic Peptide
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: GIP|DRUG: Modified GIP|DRUG: Normal Saline
|
| Outcome Measures: |
Primary: GIP, glucose, insulin measured frequently during infusions, baseline, 2 months, and 4 months | Secondary: GLP-1, ghrelin measured frequently during infusions, baseline, 2 months, and 4 months
|
| Sponsor/Collaborators: |
Sponsor: National Institute on Aging (NIA)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
41
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2003-02
|
| Completion Date: |
2006-12
|
| Results First Posted: |
|
| Last Update Posted: |
2013-11-28
|
| Locations: |
National Institute on Aging, Clinical Research Branch, Baltimore, Maryland, 21225, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00239707
|
